Phaseline

Targets › GD2

GD2: drug programs, companies and trials

29 programs from 26 companies in 40 trials: 23 Phase 1, 13 Phase 2, 4 Phase 3; Oncology; next expected readout Dec 2026.

Open in Phaseline: the race on GD2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyDinutuximab beta
Anti-GD2 monoclonal antibody
GD2Phase 3Neuroblastoma (NB); NeuroblastomaDec 2026
National Cancer Institute (NCI)Dinutuximab
Anti-GD2 monoclonal antibody
GD2Phase 3Ganglioneuroblastoma, Nodular; Recurrent NeuroblastomaMar 2027
New Approaches to Neuroblastoma Therapy ConsortiumDinutuximab
Anti-GD2 chimeric monoclonal antibody
GD2Phase 2NeuroblastomaDec 2026
Sun Yat-Sen University Cancer CenterNaxitamab
Monoclonal antibody targeting GD2 ganglioside
GD2Phase 2NeuroblastomaDec 2026
Anna RaciborskaNaxitamab
Anti-GD2 monoclonal antibody
GD2Phase 2Ewing SarcomaMay 2027
Children's Oncology GroupDinutuximab
Anti-GD2 monoclonal antibody
GD2Phase 2Ganglioneuroblastoma, Nodular; High Risk NeuroblastomaSep 2027
Sichuan Cancer Hospital and Research InstituteNituzumab
anti-GD2 monoclonal antibody
GD2Phase 2Nasopharyngeal CarcinomaOct 2027
St. Jude Children's Research Hospitalhu14.18K322A
Anti-GD2 monoclonal antibody
GD2Phase 2Neuroblastoma RecurrentFeb 2028
Children's Hospital Los AngelesDinutuximab
anti-GD2 monoclonal antibody
GD2Phase 2NeuroblastomaNov 2028
Tianjin Medical University Cancer Institute and HospitalDinutuximab Beta
Anti-GD2 monoclonal antibody
GD2Phase 2Neuroblastoma (NB)Dec 2028
Memorial Sloan Kettering Cancer CenterDANYELZA
anti-GD2 monoclonal antibody
GD2Phase 2High-risk NeuroblastomaJul 2029
Giselle ShollerNaxitamab
Anti-GD2 monoclonal antibody (IgG1)
GD2Phase 2NeuroblastomaSep 2029
Renaissance Pharmahu14.18K322A
monoclonal anti-GD2 antibody
GD2Phase 2High-Risk NeuroblastomaMar 2031
Nationwide Children's HospitalDinutuximab
Anti-GD2 monoclonal antibody
GD2Phase 1Relapsed NeuroblastomaDec 2026
Emory UniversityDinutuximab
Anti-GD2 monoclonal antibody
GD2Phase 1NeuroblastomaDec 2026
Bambino Gesù Hospital and Research InstituteGD2-CART01 (iC9-GD2-CAR T-cells)
CAR T cell therapy targeting GD2 with inducible Caspase 9 suicide gene
GD2Phase 1Neuroblastoma; Brain Tumor, PediatricDec 2026
University College, LondonhBRCA84D CAR T cells
CAR-T cells targeting B7-H3
B7H3, GD2Phase 1Neuroblastoma; Diffuse Midline Glioma, H3 K27M-Mutant; SarcomaDec 2026
Beijing BiotechEB-DART-NK01
Allogeneic dual-target CAR-NK cells (DLL3/CD56, DLL3/GD2, or CD56/GD2)
DLL3, CD56, GD2Phase 1Small Cell Lung Cancer (SCLC)Feb 2027
Baylor College of MedicineC7R-GD2.CART cells
Anti-GD2 CAR-T cell therapy
GD2Phase 1Diffuse Intrinsic Pontine Glioma; Relapsed NeuroblastomaFeb 2027
Princess Maxima Center for Pediatric Oncologyanti-GD2-800CW
anti-GD2 antibody conjugated to near-infrared fluorophore (800CW) for intra-operative dete
GD2Phase 1NeuroblastomaApr 2027
Merck KGaAM3554
anti-GD2 antibody-drug conjugate
GD2Phase 1Advanced Solid TumorApr 2027
Beijing BiotechEB-DTKN-401
Dual-target CSPG4/GD2 CAR-NK cells
CSPG4, GD2Phase 1Unresectable MelanomaJun 2027
Steven DuBois, MDNaxitamab
Recombinant humanized anti-GD2 monoclonal antibody
GD2Phase 1NeuroblastomaJul 2027
M.D. Anderson Cancer CenterNaxitamab
Anti-GD2 monoclonal antibody
GD2Phase 1Metastatic Triple-Negative Breast CancerJul 2028
UNC Lineberger Comprehensive Cancer CenteriC9.GD2.CAR.IL-15 T-cells
CAR-T cells targeting GD2 with IL-15 co-expression and inducible caspase-9 safety switch
GD2, IL15Phase 1NeuroblastomaMay 2030
Princess Maxima Center for Pediatric OncologyDinutuximab beta
Anti-GD2 monoclonal antibody
GD2Phase 1NeuroblastomaJul 2030
University of BirminghamDinutuximab beta
Anti-GD2 monoclonal antibody
GD2Phase 1Relapsed NeuroblastomaDec 2030
Chang Gung Memorial HospitalDinutuximab-beta
Anti-GD2 monoclonal antibody
GD2Phase 1High Risk NeuroblastomaDec 2032
Baylor College of MedicineiC9-GD2-CAR-VZV-CTLs
GD2-targeted CAR-T cells with inducible caspase-9 safety switch and VZV-specificity
GD2Phase 1OsteosarcomaOct 2034

Conditions

Neuroblastoma (14) Relapsed Neuroblastoma (3) Neuroblastoma (NB) (3) Ganglioneuroblastoma, Nodular (2) Small Cell Lung Cancer (SCLC) (2) High Risk Neuroblastoma (2) Brain Tumor, Pediatric (1) Recurrent Neuroblastoma (1) Diffuse Intrinsic Pontine Glioma (1) Neuroblastoma Recurrent (1) Metastatic Triple-Negative Breast Cancer (1) Diffuse Midline Glioma, H3 K27M-Mutant (1)

Modalities

mixed (12), antibody (7), small molecule (5), other (4), protein or peptide (1)

Companies

Baylor College of Medicine (2) Princess Maxima Center for Pediatric Oncology (2) Beijing Biotech (2) Bambino Gesù Hospital and Research Institute (1) Children's Hospital Los Angeles (1) National Cancer Institute (NCI) (1) St. Jude Children's Research Hospital (1) Nationwide Children's Hospital (1) M.D. Anderson Cancer Center (1) University College, London (1) Giselle Sholler (1) Renaissance Pharma (1) Tianjin Medical University Cancer Institute and Hospital (1) Anna Raciborska (1) UNC Lineberger Comprehensive Cancer Center (1) Emory University (1) New Approaches to Neuroblastoma Therapy Consortium (1) Federal Research Institute of Pediatric Hematology, Oncology and Immunology (1) Memorial Sloan Kettering Cancer Center (1) Merck KGaA (1)

Related targets

B7H3 (1) CSPG4 (1) IL15 (1) DLL3 (1) CD56 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.